Credit Suisse’s Avanos Medical AVNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $1.4M | Buy |
70,238
+1,419
| +2% | +$27.4K | ﹤0.01% | 2073 |
|
|
2023
Q4 | $1.54M | Buy |
68,819
+9,133
| +15% | +$189K | ﹤0.01% | 2056 |
|
|
2023
Q3 | $1.21M | Sell |
59,686
-2,202
| -4% | -$49.9K | ﹤0.01% | 2176 |
|
|
2023
Q2 | $1.58M | Buy |
61,888
+3,675
| +6% | +$96.8K | ﹤0.01% | 2085 |
|
|
2023
Q1 | $1.73M | Buy |
58,213
+2,972
| +5% | +$86.3K | ﹤0.01% | 1968 |
|
|
2022
Q4 | $1.49M | Buy |
55,241
+11,038
| +25% | +$270K | ﹤0.01% | 2056 |
|
|
2022
Q3 | $964K | Buy |
44,203
+458
| +1% | +$12K | ﹤0.01% | 2360 |
|
|
2022
Q2 | $1.2M | Sell |
43,745
-3,074
| -7% | -$88.3K | ﹤0.01% | 2259 |
|
|
2022
Q1 | $1.57M | Sell |
46,819
-535
| -1% | -$17.2K | ﹤0.01% | 2244 |
|
|
2021
Q4 | $1.64M | Buy |
47,354
+2,604
| +6% | +$84.2K | ﹤0.01% | 2942 |
|
|
2021
Q3 | $1.4M | Sell |
44,750
-6,042
| -12% | -$205K | ﹤0.01% | 3085 |
|
|
2021
Q2 | $1.88M | Buy |
50,792
+5,269
| +12% | +$218K | ﹤0.01% | 2913 |
|
|
2021
Q1 | $1.99M | Sell |
45,523
-22,469
| -33% | -$1.05M | ﹤0.01% | 2826 |
|
|
2020
Q4 | $3.12M | Buy |
67,992
+26,101
| +62% | +$1.09M | ﹤0.01% | 2479 |
|
|
2020
Q3 | $1.39M | Sell |
41,891
-2,983
| -7% | -$95.3K | ﹤0.01% | 2700 |
|
|
2020
Q2 | $1.32M | Buy |
44,874
+10,198
| +29% | +$295K | ﹤0.01% | 2709 |
|
|
2020
Q1 | $933K | Sell |
34,676
-3,282
| -9% | -$98K | ﹤0.01% | 2704 |
|
|
2019
Q4 | $1.28M | Sell |
37,958
-7,772
| -17% | -$281K | ﹤0.01% | 2954 |
|
|
2019
Q3 | $1.71M | Buy |
45,730
+739
| +2% | +$28.2K | ﹤0.01% | 2594 |
|
|
2019
Q2 | $1.96M | Sell |
44,991
-2,643
| -6% | -$113K | ﹤0.01% | 2464 |
|
|
2019
Q1 | $2.03M | Sell |
47,634
-13,174
| -22% | -$590K | ﹤0.01% | 2358 |
|
|
2018
Q4 | $2.72M | Sell |
60,808
-5,265
| -8% | -$276K | ﹤0.01% | 2011 |
|
|
2018
Q3 | $4.53M | Sell |
66,073
-9,097
| -12% | -$585K | ﹤0.01% | 1769 |
|
|
2018
Q2 | $4.3M | Buy |
75,170
+13,493
| +22% | +$713K | ﹤0.01% | 1834 |
|
|
2018
Q1 | $2.84M | Sell |
61,677
-12,443
| -17% | -$591K | ﹤0.01% | 2138 |
|
|
2017
Q4 | $3.42M | Sell |
74,120
-22,646
| -23% | -$1.04M | ﹤0.01% | 2041 |
|
|
2017
Q3 | $4.36M | Buy |
96,766
+21,509
| +29% | +$918K | ﹤0.01% | 1874 |
|
|
2017
Q2 | $2.96M | Sell |
75,257
-9,470
| -11% | -$358K | ﹤0.01% | 1969 |
|
|
2017
Q1 | $3.23M | Buy |
84,727
+3,917
| +5% | +$153K | ﹤0.01% | 1976 |
|
|
2016
Q4 | $2.99M | Sell |
80,810
-14,676
| -15% | -$525K | ﹤0.01% | 2103 |
|
|
2016
Q3 | $3.31M | Buy |
95,486
+16,080
| +20% | +$563K | ﹤0.01% | 1980 |
|
|
2016
Q2 | $2.58M | Buy |
79,406
+39,238
| +98% | +$1.2M | ﹤0.01% | 2141 |
|
|
2016
Q1 | $1.15M | Sell |
40,168
-10,896
| -21% | -$290K | ﹤0.01% | 2616 |
|
|
2015
Q4 | $1.71M | Sell |
51,064
-19,019
| -27% | -$591K | ﹤0.01% | 2393 |
|
|
2015
Q3 | $1.99M | Sell |
70,083
-12,721
| -15% | -$444K | ﹤0.01% | 2257 |
|
|
2015
Q2 | $3.35M | Buy |
82,804
+43,395
| +110% | +$1.95M | ﹤0.01% | 2106 |
|
|
2015
Q1 | $1.94M | Sell |
39,409
-125,494
| -76% | -$5.81M | ﹤0.01% | 2417 |
|
|
2014
Q4 | $7.5M | Buy |
+164,903
| New | +$6.48M | 0.01% | 1471 |
|
Other funds holding AVNS
RC
WHG
PIM
Credit Suisse's AVNS Position: Q1 2024 in Review
Credit Suisse increased its Avanos Medical (AVNS) stake by 2.1% in Q1 2024, buying an estimated $27.4K and bringing the position to 70,238 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2073.
Credit Suisse first reported a position in AVNS in Q4 2014 and has held it in 38 quarters since. The position peaked at $7.5M in Q4 2014. 261 funds tracked by Wall St. Rank hold AVNS as of Q1 2024.
- Credit Suisse held 70,238 shares of Avanos Medical worth $1.4M as of Q1 2024.
- Credit Suisse bought 1,419 Avanos Medical shares in Q1 2024, an estimated $27.4K.
- Avanos Medical made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2073 holding.
- Credit Suisse first reported a position in Avanos Medical in Q4 2014 and has held it in 38 quarters since.
- Credit Suisse's Avanos Medical position peaked at $7.5M in Q4 2014.
- 261 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.